References
- J. C. Pickup and G. Williams, Textbook of Diabetes, 3rd ed., Blackwell Science, Oxford 2003, pp. 103–114.
- T. Tella, B. Masola and S. Mukaratirwa, The effect of Psidium guajava aqueous leaf extract on liver glycogen enzymes, hormone sensitive lipase and serum lipid profile in diabetic rats, Biomed. Pharmacother. 109 (2019) 2441–2446; https://doi.org/10.1016/j.biopha.2018.11.137
- J. D. Colbert and J. A. Stone, Statin use and the risk of incident diabetes mellitus: a review of the literature, Can. J. Cardiol. 28(5) (2012) 581–589; https://doi.org/10.1016/j.cjca.2012.03.021
- T. Yada, M. Nakata, T. Shiraishi and M. Kakei, Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells, Br. J. Pharmacol. 126(5) (1999) 1205–1213; https://doi.org/10.1038/sj.bjp.0702397
- M. J. Ko, A. J. Jo, Y. J. Kim, S. H. Kang, S. Cho, S. Jo, C. Park, S. Yun, W. J. Lee and D. Park, Time- and dose-dependent association of statin use with risk of clinically relevant new-onset diabetes mellitus in primary prevention: A nationwide observational cohort study, J. Am. Heart Assoc. 8(8) (2019) e011320; https://doi.org/10.1161/JAHA.118.011320
- Z. Zhou, A. J. Curtis, M. E. Ernst, J. Ryan, S. Zoungas, R. Wolfe, J. J. McNeil, A. M. Murray, C. M. Reid, E. K. Chowdhury, R. L. Woods, A. M. Tonkin and M. R. Nelson, Comparison of statins for primary prevention of cardiovascular disease and persistent physical disability in older adults, Eur. J. Clin. Pharmacol. 78(3) (2022) 467–476; https://doi.org/10.1007/s00228-021-03239-1
- K. K. Koh, P. C. Oh, I. Sakuma, Y. Lee, S. H. Han and E. K. Shin, Rosuvastatin dose-dependently improves flow-mediated dilation, but reduces adiponectin levels and insulin sensitivity in hyper-cholesterolemic patients, Int. J. Cardiol. 15(223) (2016) 488–493; https://doi.org/10.1016/j.ij-card.2016.08.051
- P. M. Ridker, E. Danielson, F. A. H. Fonseca, J. Genest, A. M. Gotto, Jr., J. J. Kastelein, W. Koenig, P. Libby, A. J. Lorenzatti, J. G. MacFadyen, B. G. Nordestgaard, J. Shepherd, J. T. Willerson and R. J. Glynn (for JUPITER Study Group), Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N. Engl. J. Med. 359(21) (2008) 2195–2207; https://doi.org/10.1056/NEJMoa0807646
- G. Danaei, L. A. Garcia Rodriguez, O. Fernandez Cantero and M. A Hernan, Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival, Diabetes Care 36(5) (2013) 1236–1240; https://doi.org/10.2337/dc12-1756
- K. L. Wang, C.-J. Liu, T.-F. Chao, C.-M. Huang, C.-H. Wu, S.-J. Chen, T.-J. Chen, S.-J. Lin and C.-E. Chiang, Statins, risk of diabetes, and implications on outcomes in the general population, J. Am. Coll. Cardiol. 60(14) (2012) 1231–1238; https://doi.org/10.1016/j.jacc.2012.05.019
- N. Sattar, D. Preiss, H. M. Murray, P. Welsh, B. M. Buckley, A. J. M. de Craen, S. R. K. Seshasai, J. J. McMurray, D. J. Freeman, J. W. Jukema, P. W. Macfarlane, C. J. Packard, D. J. Stott, R. G. Westendorp, J. Shepherd, B. R. Davis, S. L. Pressel, R. Marchioli, R. M. Marfisi, A. P. Maggioni, L. Tavazzi, G. Tognoni, J. Kjekshus, T. R. Pedersen, T. J. Cook, A. M. Gotto, M. B. Clearfield, J. R. Downs, H. Nakamura, Y. Ohashi, K. Mizuno, K. K. Ray and I. Ford, Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials, Lancet 375(9716) (2010) 735–742; https://doi.org/10.1016/S0140-6736(09)61965-6
- D. J. Freeman, J. Norrie, N. Sattar, R. D. G. Neely, S. M. Cobbe, I. Ford, C. Isles, A. R. Lorimer, P. W. Macfarlane, J. H. McKillop, C. J. Packard, J. Shepherd and A. Gaw, Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland coronary prevention study, Circulation 103(3) (2001) 357–362; https://doi.org/10.1161/01.cir.103.3.357
- S. Lim, I. Sakuma, M. J. Quon and K. K. Koh, Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality, Int. J. Cardiol. 167 (2013) 1696–1702; https://doi.org/10.1016/j.ijcard.2012.10.037
- S. Parida, T. R. Swain, S. N. Routray and R. Maiti, Effect of atorvastatin on glycaemic parameters in normoglycaemic and prediabetic subjects: A prospective, panel study, J. Clin. Diagn. Res. 11(2) (2017) FC04-FC09; https://doi.org/10.7860/JCDR/2017/23741.9427
- M. J. Crespo and J. Quidgley, Simvastatin, atorvastatin, and pravastatin equally improve the hemo-dynamic status of diabetic rats, World J. Diabetes 6(10) (2015) 1168–1178; https://doi.org/10.4239/wjd.v6.i10.1168
- J. J. Min, B. S. Shin, J. H. Lee, Y. Jeon, D. K. Ryu, S. Kim and Y. H. Shin, Effects of pravastatin on type 1 diabetic rat heart with or without blood glycemic control, J. Diabetes Res. 28 (2018) Article ID 1067853 (9 pages); https://doi.org/10.1155/2018/1067853
- N. Ozturk, N. Yaras, A. Ozmen and S. Ozdemir, Long-term administration of rosuvastatin prevents contractile and electrical remodelling of diabetic rat heart, J. Bioenerg. Biomembr. 45(4) (2013) 343–352; https://doi.org/10.1007/s10863-013-9514-z
- K. Tarhzaoui, P. Valensi, G. Leger, F. Cohen-Boulakia, R. Lestrade and A. Behar, Rosuvastatin positively changes nerve electrophysiology in diabetic rats, Diabetes Metab. Res. Rev. 25(3) (2009) 272–278; https://doi.org/10.1002/dmrr.920
- D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher and R. C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia 28(7) (1985) 412–419; https://doi.org/10.1007/BF00280883
- O. H. Lowry, N. J. Rosebrough, A. L. Farr and R. J. Randall, Protein measurement with the Folin phenol reagent, J. Biol. Chem. 193(1) (1951) 265–275.
- P. Subash Babu, S. Prabuseenivasan and S. Ignacimuthu, Cinnamaldehyde-a potential antidiabetic agent, Phytomedicine 14(1) (2007) 15–22; https://doi.org/10.1016/j.phymed.2006.11.005
- D. Mondol, M. N. Islam, S. Biswas, P. Jodder, S. Sana, M. A. Saleh and M. R. Islam, Investigation of the synergistic effect of glimepiride and rosuvastatin on alloxan-induced diabetic rat, J. Diabetes Metab. Disord. 19(2) (2020) 1415–1422; https://doi.org/10.1007/s40200-020-00662-6
- K. Gothandam, V. S. Ganesan, T. Ayyasamy and S. Ramalingam, Antioxidant potential of the aflavin ameliorates the activities of key enzymes of glucose metabolism in high fat diet and streptozotocin-induced diabetic rats, Redox Rep. 24(1) (2019) 41–50; https://doi.org/10.1080/13510002.2019.1624085
- I. Dhananjayan, S. Kathiroli, S. Subramani and V. Veerasamy, Ameliorating effect of betanin, a natural chromoalkaloid by modulating hepatic carbohydrate metabolic enzyme activities and glycogen content in streptozotocin-nicotinamide induced experimental rats, Biomed. Pharmacother. 88 (2017) 1069–1079; https://doi.org/10.1016/j.biopha.2017.01.146
- N. Abboud and R. Makhous, The effect of some statins on glucose blood levels in experimental animals, Res. J. Pharm. Technol. 15(6) (2022) 2661–2666; https://doi.org/10.52711/0974-360X.2022.00445
- Y. Yu, K. Ohmori, Y. Chen, C. Sato, H. Kiyomoto, K. Shinomiya, H. Takeuchi, K. Mizushige and M. Kohno, Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model, J. Am. Coll. Cardiol. 44(4) (2004) 904–913; https://doi.org/10.1016/j.jacc.2004.04.050
- T. Takagi, M. Matsuda, M. Abe, H. Kobayashi, A. Fukuhara, R. Komuro, S. Kihara, M. J. Caslake, A. McMahon, J. Shepherd, T. Funahashi and I. Shimomura, Effect of pravastatin on the development of diabetes and adiponectin production, Atherosclerosis 196(1) (2008) 114–121; https://doi.org/10.1016/j.atherosclerosis.2007.02.013
- S. Sugiyama, H. Fukushima, K. Kugiyama, H. Maruyoshi, S. Kojima, T. Funahashi, T. Sakamoto, Y. Horibata, K. Watanabe, H. Koga, K. Sugamura, F. Otsuka, I. Shimomura and H. Ogawa, Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease, Atherosclerosis 194(2) (2007) E43-E51; https://doi.org/10.1016/j.atherosclerosis.2006.08.023
- A. Keech, D. Colquhoun, J. Best, A. Kirby, R. J. Simes, D. Hunt, W. Hague, E. Beller, M. Arulchelvam, J. Baker and A. Tonkin (for LIPID study group), Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial, Diabetes Care 26(10) (2003) 2713–2721; https://doi.org/10.2337/diacare.26.10.2713
- J. Shepherd, G. J. Blauw, M. B. Murphy, E. L. Bollen, B. M. Buckley, S. M. Cobbe, I. Ford, A. Gaw, M. Hyland, J. W. Jukema, A. M. Kamper, P. W. Macfarlane, A. E. Meinders, J. Norrie, C. J. Packard, I. J. Perry, D. J. Stott, B. J. Sweeney, C. Twomey and R. G. Westendorp (for PROSPER study group), PRO-spective study of pravastatin in the elderly at risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, Lancet 360(9346) (2002) 1623–1630; https://doi.org/10.1016/s0140-6736(02)11600-x.9
- S. Simsek, C. G. Schalkwijk and B. H. Wolffenbuttel, Effects of rosuvastatin and atorvastatin on glycaemic control in type 2 diabetes – the CORALL study, Diabet Med. 29(5) (2012) 628–631; https://doi.org/10.1111/j.1464-5491.2011.03553.x
- T. Katabami, M. Murakami, S. Kobayashi, T. Matsui, M. Ujihara, S. Takagi, M. Higa, T. Ichijo, A. Ohta and Y. Tanaka, Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia, J. Int. Med. Res. 42(2) (2014) 457–467; https://doi.org/10.1177/0300060513507648
- D. Xilifu, Z. Tuerxun, B. Nuermaimaiti, A. Aili, N. Rehemu, H. Sun and X. Zhang, Effects of rosuvastatin on serum glucose and insulin in hyperuricemic rats, BMC Pharmacol. Toxicol. 23(1) (2022) Article ID 66 (10 pages); https://doi.org/10.1186/s40360-022-00595-1
- M. S. Kostapanos, H. J. Milionis, A. D. Agouridis, C. V. Rizos and M. S. Elisaf, Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose, Int. J. Clin. Pract. 63 (2009) 1308–1313; https://doi.org/10.1111/j.1742-1241.2009.02101.x
- D. Preiss, S. R. Seshasai, P. Welsh, S. A. Murphy, J. E. Ho, D. D. Waters, D. A. DeMicco, P. Barter, C. P. Cannon, M. S. Sabatine, E. Braunwald, J. J. Kastelein, J. A. de Lemos, M. A. Blazing, T. R. Pedersen, M. J. Tikkanen, N. Sattar and K. K. Ray, Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis, JAMA 305(24) (2011) 2556–2564; https://doi.org/10.1001/jama.2011.860
- K. K. Koh, M. J. Quon, S. H. Han, Y. Lee, S. J. Kim, J. B. Park and E. K. Shin, Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients, Atherosclerosis 204(2) (2009) 483–490; https://doi.org/10.1016/j.atherosclerosis.2008.09.021
- J. H. Kim, M. Lee, J. Shin, S. Lee, J. Lee, S. J. You, K. H. Yoon and S. A. Chang, Effects of pravastatin on serum adiponectin levels in female patients with type 2 diabetes mellitus, Atherosclerosis 227(2) (2013) 355–359; https://doi.org/10.1016/j.atherosclerosis.2013.01.045
- N. Thongtang, M. Ai, S. Otokozawa, T. V. Himbergen, B. F. Asztalos, K. Nakajima, E. Stein, P. H. Jones and E. J. Schaefer, Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation, Am. J. Cardiol. 107(3) (2011) 387–392; https://doi.org/10.1016/j.amjcard.2010.09.031
- K. S. Shali, N. P. P. Soumya, S. Mondal and S. Mini, Hepatoprotective effect of morin via regulating the oxidative stress and carbohydrate metabolism in STZ induced diabetic rats, Bioact. Compd. Health Dis. 5(3) (2022) 53–66; https://doi.org/10.31989/bchd.v5i2.893
- E. K. Ainscow, C. Zhao and G. A. Rutter, Acute overexpression of lactate dehydrogenase-A perturbs beta-cell mitochondrial metabolism and insulin secretion, Diabetes 49(7) (2000) 1149–1155; https://doi.org/10.2337/diabetes.49.7.1149
- R. Chen, M. Meseck, R. C. McEvoy and S. L. Woo, Glucose-stimulated and self-limiting insulin production by glucose 6-phosphatase promoter driven insulin expression in hepatoma cells, Gene Ther. 7(21) (2000) 1802–1809; https://doi.org/10.1038/sj.gt.3301306
- D. Gupta, J. Raju, J. Prakash R. and N. Z. Baquer, Change in the lipid profile, lipogenic and related enzymes in the livers of experimental diabetic rats: effect of insulin and vanadate, Diabetes Res. Clin. Pract. 46(1) (1999) 1–7; https://doi.org/10.1016/s0168-8227(99)00067-4
- K. Aoki, T. Saito, S. Satoh, K. Mukasa, M. Kaneshiro, S. Kawasaki, A. Okamura and H. Sekihara, Dehydroepiandrosterone suppresses the elevated hepatic glucose-6-phosphatase and fructose-1,6-bisphosphatase activities in C57BL/Ksj-db/db mice: comparison with troglitazone, Diabetes 48(8) (1999) 1579–1585; https://doi.org/10.2337/diabetes.48.8.1579
- Y. Xu, B. W. Osborne and R. C. Stanton, Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of PKA, which contributes to oxidative stress in rat kidney cortex, Am. J. Physiol. Renal Physiol. 289(5) (2005) F1040-F1047; https://doi.org/10.1152/ajprenal.00076.2005
- B. M. McDermott, P. R. Flatt and J. J. Strain, Effects of copper deficiency and experimental diabetes on tissue antioxidant enzyme levels in rats, Ann. Nutr. Metab. 38(5) (1994) 263–269; https://doi.org/10.1159/000177820